Literature DB >> 21918794

Evaluation of recurrence after photodynamic therapy with topical methylaminolaevulinate for 157 basal cell carcinomas in 90 patients.

Rune Lindberg-Larsen1, Henrik Sølvsten, Knud Kragballe.   

Abstract

The aim of this study was to evaluate the effect of photodynamic therapy with topical methylaminolevulinate for the treatment of basal cell carcinomas in a single dermatological department. Ninety patients (34.4% men and 65.6% women) with a total of 157 basal cell carcinomas (111 superficial, 40 nodular, 6 unknown) were treated. Primary endpoint was clinically observed recurrence verified by biopsy 3, 6 and 12 months after treatment, then once a year. Estimated patient recurrence rates were 7% at 3 months, 19% at 6 months, 27% at 12 months and 31% at 24 months. Patients aged over 60 years had significantly higher estimated recurrence rates compared with patients aged 60 years or under (at 12 months, 35% vs. 19%, p?=?0.01). Estimated recurrence rates for tumours was 4% at 3 months, 11% at 6 months, 16% at 12 months and 19% at 24 months. There were significantly higher estimated recurrence rates for nodular basal cell carcinomas compared with superficial basal cell carcinomas (at 12 months, 28% vs. 13%, p?=?0.008). In conclusion, photodynamic therapy is only appropriate for treatment of superficial basal cell carcinoma, and, age above 60 years and histology showing nodular basal cell carcinoma are independent risk factors for developing a recurrent basal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21918794     DOI: 10.2340/00015555-1198

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  9 in total

Review 1.  The application of physical pretreatment in photodynamic therapy for skin diseases.

Authors:  Dihui Liu; Shuang Zhao; Jinmao Li; Mingliang Chen; Lisha Wu
Journal:  Lasers Med Sci       Date:  2021-01-06       Impact factor: 3.161

2.  C6-pyridinium ceramide sensitizes SCC17B human head and neck squamous cell carcinoma cells to photodynamic therapy.

Authors:  Nithin B Boppana; Ursula Stochaj; Mohamed Kodiha; Alicja Bielawska; Jacek Bielawski; Jason S Pierce; Mladen Korbelik; Duska Separovic
Journal:  J Photochem Photobiol B       Date:  2015-01-10       Impact factor: 6.252

3.  Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy.

Authors:  Pritam Thapa; Mengjie Li; Moses Bio; Pallavi Rajaputra; Gregory Nkepang; Yajing Sun; Sukyung Woo; Youngjae You
Journal:  J Med Chem       Date:  2016-03-22       Impact factor: 7.446

Review 4.  Photodynamic Therapy for Non-Melanoma Skin Cancers.

Authors:  Diana K Cohen; Peter K Lee
Journal:  Cancers (Basel)       Date:  2016-10-04       Impact factor: 6.639

5.  Accurate early prediction of tumour response to PDT using optical coherence angiography.

Authors:  M A Sirotkina; A A Moiseev; L A Matveev; V Y Zaitsev; V V Elagin; S S Kuznetsov; G V Gelikonov; S Y Ksenofontov; E V Zagaynova; F I Feldchtein; N D Gladkova; A Vitkin
Journal:  Sci Rep       Date:  2019-04-24       Impact factor: 4.379

Review 6.  Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature.

Authors:  A J G Leus; M Frie; M S Haisma; J B Terra; B E C Plaat; R J H M Steenbakkers; G B Halmos; E Rácz
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-03-30       Impact factor: 6.166

7.  Six years of experience in photodynamic therapy for Basal cell carcinoma: results and fluorescence diagnosis from 191 lesions.

Authors:  M Fernández-Guarino; A Harto; B Pérez-García; A Royuela; P Jaén
Journal:  J Skin Cancer       Date:  2014-09-14

8.  Long-term recurrence of nonmelanoma skin cancer after topical methylaminolevulinate photodynamic therapy in a dermato-oncology department.

Authors:  Joana Cabete; Margarida Rafael; Mariana Cravo; Cecília Moura; Fernanda Sachse; Manuela Pecegueiro
Journal:  An Bras Dermatol       Date:  2015 Nov-Dec       Impact factor: 1.896

9.  Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells.

Authors:  Pritam Thapa; Mengjie Li; Radha Karki; Moses Bio; Pallavi Rajaputra; Gregory Nkepang; Sukyung Woo; Youngjae You
Journal:  ACS Omega       Date:  2017-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.